Compounds > 3'-fluoro-2',3'-dideoxyuridine
Page last updated: 2024-12-08

3'-fluoro-2',3'-dideoxyuridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID162450
CHEMBL ID244975
SCHEMBL ID1835932
MeSH IDM0164120

Synonyms (27)

Synonym
41107-56-6
2,4(1h,3h)-pyrimidinedione, 1-(2,3-dideoxy-3-fluoro-b-d-erythro-pentofuranosyl)-
207128-22-1
fddurd
1-[(2r,4s,5r)-4-fluoro-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione
3'-fluoro-2',3'-dideoxyuridine
3'-fddu
2',3'-dideoxy-3'-fluorouridine, 95%
CHEMBL244975
2',3'-dideoxy-3'-fluorouridine
1-[(2r,4s,5r)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
ec 415-360-8
5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidine)-3- fluoro-2-hydroxymethyltetrahydrofuran
AKOS015913031
SCHEMBL1835932
BKIUEHLYJFLWPK-SHYZEUOFSA-N
1-(2,3-dideoxy-3-fluoro-beta-d-erythropentofuranosyl)uracil
2',3'-dideoxy-3'-florouridine
2'3'-dideoxy-3'-fluorouridine
2',3'-dide-oxy-3'-fluorouridine
1-(2,3-dideoxy-3-fluoro-beta-d-ribofuranosyl)-uracil
mfcd00192015
F12894
1-((2r,4s,5r)-4-fluoro-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione
5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidine)-3-fluoro-2-hydroxymethyltetrahydrofuran
1-[(2r,4s,5r)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione
DTXSID901034059
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1ED500.04000.00020.99359.8000AID105582
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID254534Inhibitory constant against Plasmodium falciparum deoxyuridine 5'-triphosphate nucleotidohydrolase expressed in Escherichia coli BL21 (DE3) cells; nd = not determined2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target.
AID254503Inhibitory constant against human deoxyuridine 5'-triphosphate nucleotidohydrolase expressed in Escherichia coli BL21 (DE3) cells; nd = not determined2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target.
AID255966In vitro cytotoxicity aganist rat skeletal myoblasts (L-6 cells) after 72 hours2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target.
AID81438Dose required to inhibit cytopathic effect of human immunodeficiency virus replication in MT-4 cells.1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Synthesis and anti-HIV activity of different sugar-modified pyrimidine and purine nucleosides.
AID255964In vitro inhibitory activity against Plasmodium falciparum as [3H]hypoxanthine (50 uL) incorporation at 37C2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target.
AID255969Inhibitory constant against Trypanosoma brucei rhodesiense upon incubation with the compound at 37 degrees C under a 5% CO2 atmosphere for 72 hours2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target.
AID105582Inhibitory activity against HIV-1 replication in MT-4 cells1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
3'-Fluoro-2',3'-dideoxy-5-chlorouridine: most selective anti-HIV-1 agent among a series of new 2'- and 3'-fluorinated 2',3'-dideoxynucleoside analogues.
AID255970In vitro growth inhibitory activity against Leishmania donovani amastigotes at 37 degrees C under a 5% CO2 atmosphere for 96 hours2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target.
AID255973In vitro growth inhibitory activity against Trypanosoma cruzi in rat L-6 cells upon incubation at 37 degrees C in 5% CO2 atmosphere for 4 days2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target.
AID235486Selectivity index is the ratio of ED50 and CD50 values against inhibition of HIV-1 in MT-4 cells1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
3'-Fluoro-2',3'-dideoxy-5-chlorouridine: most selective anti-HIV-1 agent among a series of new 2'- and 3'-fluorinated 2',3'-dideoxynucleoside analogues.
AID81069Cytotoxic dose required to reduce the viability of normal uninfected MT-4 cells.1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Synthesis and anti-HIV activity of different sugar-modified pyrimidine and purine nucleosides.
AID254450Inhibitory constant against Leishmania major deoxyuridine 5'-triphosphate nucleotidohydrolase; nd = not determined2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target.
AID235875Ratio of CD50 to ED50 rvaluated for inhibition of HIV replication in MT-4 cells1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Synthesis and anti-HIV activity of different sugar-modified pyrimidine and purine nucleosides.
AID105376Cytotoxic dose in MT-4 cells1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
3'-Fluoro-2',3'-dideoxy-5-chlorouridine: most selective anti-HIV-1 agent among a series of new 2'- and 3'-fluorinated 2',3'-dideoxynucleoside analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (66.67)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.19 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
thymidine
[no description available]		1.9710pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
uridine
[no description available]		6.9710uridinesdrug metabolite;
fundamental metabolite;
human metabolite
cordycepin
[no description available]		1.97103'-deoxyribonucleoside;
adenosines		antimetabolite;
nucleoside antibiotic
deoxycytidine
[no description available]		1.9710pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
2'-deoxyadenosine
2'-deoxyformycin A: RN not in Chemline 9/85; RN and structure given in first source		1.9710purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
dideoxyadenosine
Dideoxyadenosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.		1.9710adenosines;
purine 2',3'-dideoxyribonucleoside		EC 3.5.4.4 (adenosine deaminase) inhibitor;
EC 4.6.1.1 (adenylate cyclase) inhibitor
alovudine
[no description available]		2.3720pyrimidine 2',3'-dideoxyribonucleoside
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		2.6630azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
3'-azido-2',3'-dideoxyuridine
[no description available]		1.9710
3'-azido-2',3'-dideoxy-5-methylcytidine
3'-azido-2',3'-dideoxy-5-methylcytidine: inhibits reproduction of AIDS virus in cultured cells		1.9710
1-(2,3-dideoxy-2-fluoropentofuranosyl)cytosine
[no description available]		1.9710
2',3'-didehydro-2',3'-dideoxyuridine
[no description available]		2.420
2',3'-dideoxyuridine
[no description available]		2.0510pyrimidine 2',3'-dideoxyribonucleoside
adenosine 2',3'-ribo-epoxide
adenosine 2',3'-ribo-epoxide: structure		1.9710
3'-azido-2',3'-dideoxyadenosine
[no description available]		2.3720
3'-azido-2',3'-dideoxycytidine
[no description available]		1.9710
raluridine
raluridine: inhibitor of HIV; structure given in first source		2.3820
(2R,3S,5S)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-3-oxolanol
[no description available]		1.97103'-deoxyribonucleoside;
purines
3'-azido-2',3'-dideoxyuridine
3'-azido-2',3'-dideoxyuridine: structure given in first source		6.9710
deoxyguanosine
[no description available]		1.9710purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		02.6630
Cell Transformation, Viral
An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.		01.9710